GLP-1 Agonists Explained: Semaglutide, Tirzepatide & Retatrutide

GLP-1 receptor agonists have become one of the most talked-about classes of compounds in modern biomedical research. From semaglutide to tirzepatide to the emerging triple-agonist retatrutide, these peptides are reshaping our understanding of metabolic regulation — and generating unprecedented levels of clinical evidence in the process.

This guide provides a comprehensive, science-based overview of GLP-1 agonists: what they are, how they work, what differentiates the major compounds, and what the published research reveals.

What Are GLP-1 Receptor Agonists?

GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring incretin hormone produced by L-cells in the small intestine in response to food intake. It plays a central role in glucose homeostasis by:

• Stimulating insulin secretion in a glucose-dependent manner
• Suppressing glucagon release from pancreatic alpha cells
• Slowing gastric emptying, which modulates nutrient absorption
• Acting on central nervous system pathways that regulate appetite and satiety

GLP-1 receptor agonists are synthetic compounds designed to mimic or enhance the action of natural GLP-1. They bind to the same receptors but are engineered to resist the rapid degradation that limits natural GLP-1’s half-life (which is only 2-3 minutes in circulation).

How GLP-1 Agonists Work: Mechanism of Action

GLP-1 receptor agonists produce their effects through multiple simultaneous pathways:

Pancreatic Effects

• Glucose-dependent insulin secretion — Unlike older diabetes medications, GLP-1 agonists only stimulate insulin release when blood glucose is elevated, significantly reducing hypoglycaemia risk
• Glucagon suppression — Reduces hepatic glucose output by inhibiting glucagon secretion from alpha cells
• Beta cell preservation — Preclinical evidence suggests GLP-1 agonists may promote beta cell proliferation and reduce apoptosis

Central Nervous System Effects

• Appetite regulation — GLP-1 receptors in the hypothalamus and brainstem modulate hunger and satiety signals
• Reward pathway modulation — Emerging research suggests GLP-1 agonists may influence dopaminergic reward circuits, potentially reducing compulsive eating behaviours
• Neuroprotection — GLP-1 receptor activation has shown neuroprotective effects in preclinical models of Alzheimer’s and Parkinson’s disease

Gastrointestinal Effects

• Delayed gastric emptying — Slows the rate at which food leaves the stomach, promoting satiety and moderating postprandial glucose spikes

The Major GLP-1 Agonists Compared

Semaglutide

Semaglutide is arguably the most well-known GLP-1 receptor agonist, developed by Novo Nordisk and available in injectable (Ozempic, Wegovy) and oral (Rybelsus) formulations.

Key research findings:

• STEP trials — The landmark STEP clinical trial programme demonstrated mean weight reduction of 14.9% with semaglutide 2.4mg weekly versus 2.4% with placebo over 68 weeks (Wilding et al., NEJM, 2021)
• SUSTAIN trials — Demonstrated significant HbA1c reductions across multiple Phase 3 trials in type 2 diabetes
• SELECT trial — Showed 20% reduction in major adverse cardiovascular events (MACE) in overweight/obese adults, independent of diabetes status (Lincoff et al., NEJM, 2023)
• Mechanism: Pure GLP-1 receptor agonist with a 94% structural homology to native GLP-1, modified with a C-18 fatty acid chain for albumin binding (extending half-life to ~7 days)

Tirzepatide

Tirzepatide (Eli Lilly; Mounjaro, Zepbound) represents the next evolution — a dual GIP/GLP-1 receptor agonist that activates both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously.

Key research findings:

• SURMOUNT-1 — Participants receiving tirzepatide 15mg achieved mean weight reduction of 22.5% versus 2.4% with placebo over 72 weeks (Jastreboff et al., NEJM, 2022)
• SURPASS trials — Demonstrated superior HbA1c reduction compared to semaglutide 1mg in head-to-head trials
• Mechanism: The addition of GIP receptor agonism provides complementary metabolic benefits — GIP enhances insulin sensitivity in adipose tissue and may improve fat metabolism and energy expenditure beyond what GLP-1 alone achieves

Retatrutide

Retatrutide (Eli Lilly; LY3437943) is the most advanced compound in this class — a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It is currently in Phase 3 clinical trials.

Key research findings:

• Phase 2 trial — Participants receiving retatrutide 12mg achieved mean weight reduction of 24.2% at 48 weeks — the highest weight loss reported for any anti-obesity medication in clinical trials to date (Jastreboff et al., NEJM, 2023)
• Mechanism: The addition of glucagon receptor agonism increases hepatic energy expenditure and fat oxidation, promotes lipolysis, and may reduce hepatic steatosis (fatty liver). This triple mechanism addresses metabolic regulation from three complementary angles
• NAFLD/NASH potential — Early data suggests significant reductions in liver fat content, opening potential therapeutic applications beyond obesity and diabetes

Emerging Research Areas

Beyond metabolic regulation, GLP-1 agonists are being investigated across a growing range of research domains:

• Cardiovascular protection — The SELECT trial established cardiovascular risk reduction independent of glucose control, suggesting direct cardioprotective mechanisms
• Neurodegenerative disease — Multiple clinical trials are investigating semaglutide and liraglutide in Alzheimer’s disease, with preclinical evidence showing reduced amyloid plaque burden and neuroinflammation
• Addiction and reward pathways — Emerging evidence suggests GLP-1 agonists may modulate alcohol and substance use behaviours through dopaminergic pathway effects
• Non-alcoholic fatty liver disease — Retatrutide and tirzepatide have shown significant liver fat reduction in clinical trials
• Chronic kidney disease — The FLOW trial demonstrated renal protective effects of semaglutide in diabetic kidney disease
• Obstructive sleep apnoea — Tirzepatide demonstrated significant reduction in sleep apnoea severity in the SURMOUNT-OSA trial

Understanding the Differences

The evolution from single to dual to triple agonism reflects a broader shift in metabolic research — the recognition that targeting multiple complementary pathways simultaneously can produce effects greater than any single pathway intervention.

Quality and Purity in GLP-1 Research

Given the complexity of these molecules, analytical quality is paramount. GLP-1 agonists are larger peptides with sophisticated structural modifications — any impurity or degradation can fundamentally alter receptor binding affinity and biological activity.

Essential quality benchmarks:

• HPLC purity ≥98% — Verified peptide content with minimal synthesis by-products
• Mass spectrometry confirmation — Validates molecular weight and structural integrity
• Endotoxin testing — Bacterial endotoxin levels below USP thresholds
• Sterility testing — Critical for injectable research applications
• Third-party COA — Independent verification from accredited laboratories

Key Takeaways

• GLP-1 receptor agonists mimic the incretin hormone GLP-1 to regulate glucose, appetite, and metabolic function
• Semaglutide (single agonist), tirzepatide (dual agonist), and retatrutide (triple agonist) represent the evolution of this compound class
• Clinical evidence demonstrates progressive improvements in efficacy from single to multi-agonist approaches
• Research applications are expanding beyond metabolic disease into cardiovascular, neurological, hepatic, and behavioural domains
• Compound purity and third-party verification are essential for valid research outcomes

This article is provided for educational and informational purposes only. It does not constitute medical advice and is not intended to diagnose, treat, cure, or prevent any disease. All Pepora Health products are sold strictly for research purposes. Consult a qualified healthcare professional before making any health-related decisions.